- Home
- Point Of Care For Sepsis Diagnostics Market

Point of Care for Sepsis Diagnostics Market Research Report Segmented By Diagnostic Method (Biomarker Test, Molecular Diagnostics, Immunoassays, and Others), By End-User (Hospitals & Clinics, Homecare, Research Laboratories, and Others), By Pathogen (Bacteria, Fungal, and Viral), By Age (Pediatric, Adult, and Geriatric), and Region- Size, Share, Growth Analysis | Forecast (2024 2030)
- Published Date: January, 2024 | Report ID: CLS-2109 | No of pages: 250 | Format:
Point of Care For Sepsis Diagnostics Market Size (2024 – 2030)
The market size of Point of Care For Sepsis Diagnostics reached a valuation of USD 516.62 million and is expected to attain a market size of USD 1001.63 million by the conclusion of 2030. Throughout the forecast period spanning from 2024 to 2030, the market is poised to exhibit a Compound Annual Growth Rate (CAGR) of 9.92%.
POINT OF CARE FOR SEPSIS
Historically, sepsis testing faced constraints with limited availability, often necessitating conventional laboratory testing, characterized by prolonged processing times and susceptibility to human errors. Nevertheless, advancements in testing technologies have simplified sepsis detection, leading to heightened consumer demand for Point-of-Care Testing (POCT) diagnostics for sepsis. This demand encompasses innovative biomarker testing devices, at-home testing kits, and Artificial Intelligence (AI)-enabled point-of-care devices designed for the analysis and monitoring of patients. Additionally, compact POCT devices offer convenience, delivering swift results to both homecare patients and hospital settings, thereby enhancing treatment efficiency. The future outlook for the Point of Care For Sepsis Diagnostics market remains optimistic, with an increasing adoption of AI in hospitals and clinics for testing, analyzing, and monitoring purposes. Furthermore, advancements in nanotechnology have given rise to miniature and handheld POCT devices capable of facilitating rapid and early molecular-level sepsis detection.
Key Market Insights:
According to the World Health Organization (WHO), nearly 85% of sepsis cases, including fatalities, manifest in low-resource settings.
Children contribute to approximately 49 million cases of sepsis annually.
In 2022, 27% of individuals afflicted with sepsis were hospitalized, with 42% of cases resulting in death in intensive care units (WHO).
Research published by the National Institute of Health (PubMed) indicates that 60% of sepsis cases occur in patients aged 65 years and above.
Point of Care For Sepsis Diagnostics Market Drivers:
The escalating prevalence of sepsis has stimulated the demand for point-of-care sepsis diagnostics in the market.
The predominant factor fueling the demand for Point-of-Care (POC) diagnostics is the increasing incidence of sepsis, an infectious disease with the potential to compromise the immune system, leading to organ failure in chronic cases. The elderly, being more susceptible to chronic diseases due to reduced bodily function and weakened immunity, are particularly at risk. Consequently, POC diagnostics devices play a crucial role in early sepsis detection, averting fatalities such as organ failure or death. WHO reports an annual death toll of 11 million due to sepsis, with children representing a significant portion of cases. Biomarker and diagnostic marker tests are pivotal in assessing sepsis severity and identifying the pathogen, guiding targeted treatment approaches. Moreover, the compact and portable design of POC diagnostics devices enables testing in remote locations, ambulances, emergency and intensive care units, and other settings.
The growing geriatric population has intensified the demand for point-of-care for sepsis diagnostics in the market.
The burgeoning elderly population is a primary driver of the rising prevalence of sepsis, as advanced age correlates with a weakened immune system, predisposing individuals to chronic diseases like sepsis. Furthermore, elderly individuals with pre-existing conditions such as diabetes face an elevated risk of developing sepsis. Consequently, there is an increased need for POC diagnostics devices capable of promptly detecting sepsis for timely intervention. Notably, homecare testing kits, particularly bedside testing, cater to caregivers or family members of the elderly, facilitating the analysis and monitoring of sepsis severity and the prompt initiation of treatment under medical supervision.
Point of Care For Sepsis Diagnostics Market Restraints and Challenges:
Data privacy concerns in smart Point-of-Care Testing (POCT) diagnostics may diminish market demand. Smart POCT devices store patients' data on online platforms, exposing them to cybersecurity threats such as data leaks, misuse, or privacy breaches, thereby compromising patient safety.
Certain POCT devices, especially those designed for at-home care with intricate structures and functionalities, may pose challenges in handling, resulting in inaccurate or faulty results. This factor could contribute to a decline in demand for point-of-care for sepsis diagnostics in the market.
Point of Care For Sepsis Diagnostics Market Opportunities:
The Point of Care For Sepsis Diagnostics Market is poised to offer lucrative opportunities for businesses, including acquisitions, partnerships, collaborations, product launches, and agreements during the forecasted period. Additionally, the growing prevalence of sepsis, particularly among the elderly and children, coupled with the escalating demand for on-site and convenient diagnosis, is anticipated to foster the market for point-of-care for sepsis diagnostics, thereby enhancing future growth prospects.
Point of Care For Sepsis Diagnostics Market Segmentation: By Diagnostic Method
- Biomarker Test
- Molecular Diagnostics
- Immunoassays
- Others
In 2022, concerning diagnostic method segmentation, biomarker tests held the predominant market share at approximately 25.5%. These tests involve scrutinizing specific markers in the patient's blood to detect the presence of sepsis. Commonly utilized biomarkers include procalcitonin, C-reactive protein, cytokines, among others. The growth in this category is attributed to enhanced efficiency and the swift delivery of results, aiding in formulating sepsis treatment plans and assessing patient responses.
The fastest-growing segment during the forecast period is molecular diagnostics. This methodology facilitates the detection of sepsis-causing pathogens through genetic analysis, typically involving DNA or RNA sequencing. Molecular diagnostics contribute to rapid result delivery by examining various bodily fluids such as blood, urine, and cerebrospinal fluid. Additionally, portable devices like blood analyzers further support the expeditious diagnostic process.
Point of Care For Sepsis Diagnostics Market Segmentation: By End-User
- Hospitals & Clinics
- Homecare
- Research Laboratories
- Others
In 2022, within the end-user segmentation, hospitals and clinics led with a market share of approximately 32%. These healthcare facilities extensively employ various devices for on-site sepsis diagnosis, allowing immediate testing and subsequent treatment based on the results. Furthermore, Point of Care (POC) monitoring devices are utilized in hospitals to track patient progress and responses to treatments, facilitating prompt interventions in emergency situations.
The homecare segment is the most rapidly expanding category. Post-pandemic, there is a rising trend in homecare testing and monitoring, fueling the demand for POC diagnostic devices for sepsis. These devices enable individuals to conduct tests detecting early signs of infection and offer telemonitoring and teleconsultation services. Integration with mobile apps facilitates remote monitoring, particularly for vulnerable populations like geriatric patients.
Point of Care For Sepsis Diagnostics Market Segmentation: By Pathogen
- Bacteria
- Fungal
- Viral
In 2022, based on pathogen segmentation, bacteria claimed the largest market share at around 30%. Bacterial sepsis diagnostics focus on identifying common bacteria associated with sepsis, including Staphylococcus aureus, E. coli, and Klebsiella pneumoniae. Testing devices include blood culture systems, molecular diagnostic devices, rapid testing tools, and sensitivity testing.
The viral segment exhibits the highest growth during the forecast period. This involves diagnosing virus severity in sepsis, covering viruses directly or indirectly linked to sepsis (adenoviruses, influenza viruses, herpes simplex virus, etc.). Diagnostic techniques include nucleic acid testing, biomarker/diagnostic marker testing, and serological testing.
Point of Care For Sepsis Diagnostics Market Segmentation: By Age
- Pediatric
- Adult
- Geriatric
In 2022, concerning age-based segmentation, the geriatric segment held the majority market share at approximately 36%. Sepsis is often diagnosed in the elderly due to their susceptibility to medical conditions such as respiratory issues, diabetes, and immunodeficiency viruses. POC diagnostics meet the demand for at-home testing, enabling family members to monitor the health of the elderly remotely.
The pediatric segment is the most rapidly growing during the forecast period. Children, especially those under 14 and infants, may develop sepsis due to injuries, inflammation, infections, or untreated existing diseases. POC diagnostics aid in early sepsis detection in children, reducing the risk of future complications and assisting healthcare professionals in devising preventive treatments.
Point of Care For Sepsis Diagnostics Market Segmentation: Regional Analysis
- North America
- Europe
- Asia-Pacific
- South America
- Middle-East & Africa
In 2022, regional segmentation indicated that North America dominated the market with a share of about 38%. The region's advanced diagnostic devices and robust healthcare infrastructure contribute to the high demand for point-of-care sepsis diagnostics.
Asia-Pacific emerges as the fastest-growing region during the forecast period. Increasing demand for on-site diagnosis, growing trends in telehealth and telemedicine, and government support for the healthcare sector drive the demand for point-of-care sepsis diagnostics in the region.
COVID-19 Impact Analysis on the Point of Care For Sepsis Diagnostics Market:
The pandemic significantly influenced the point-of-care sepsis diagnostics market, witnessing increased demand for detecting diseases due to the virus outbreak. Sepsis, being an infectious disease, experienced heightened testing requirements. However, the shift in focus towards treating virus-infected patients resulted in a decline in demand for POCT for sepsis diagnostics. Despite this, increased digitization during the pandemic facilitated the adoption of telehealth and telemedicine services, mitigating delays in patient treatment.
Latest Developments:
Constant product innovations, rising consumer demand for early detection and rapid delivery testing devices, and increasing trends in telehealth contribute to the growing demand for point-of-care sepsis diagnostics.
In November 2022, Immunexpress introduced SepiCyte Rapid, a rapid testing device for sepsis. This product enables fast sepsis diagnosis directly from a blood draw, utilizing PCR technology to detect mRNA signatures, evaluating the severity of bacterial or pathogenic infections.
Key Players:
- Siemens
- Abbott
- AdvanDx
- Miacom Diagnostics
- Biofire Diagnostics
- Alteco Medical
- Becton Dickinson
- Wolters Kluwer
- Immunexpress
- Inflammatix
- Mbio
- Abionic
TABLE OF CONTENT
Chapter 1. Point of Care for Sepsis Diagnostics Market – Scope & Methodology
1.1 Market Segmentation
1.2 Scope, Assumptions & Limitations
1.3 Research Methodology
1.4 Primary Sources
1.5 Secondary Sources
Chapter 2. Point of Care for Sepsis Diagnostics Market – Executive Summary
2.1 Market Size & Forecast – (2024 – 2030) ($M/$Bn)
2.2 Key Trends & Insights
2.2.1 Demand Side
2.2.2 Supply Side
2.3 Attractive Investment Propositions
2.4 COVID-19 Impact Analysis
Chapter 3. Point of Care for Sepsis Diagnostics Market – Competition Scenario
3.1 Market Share Analysis & Company Benchmarking
3.2 Competitive Strategy & Development Scenario
3.3 Competitive Pricing Analysis
3.4 Supplier-Distributor Analysis
Chapter 4. Point of Care for Sepsis Diagnostics Market Entry Scenario
4.1 Regulatory Scenario
4.2 Case Studies – Key Start-ups
4.3 Customer Analysis
4.4 PESTLE Analysis
4.5 Porters Five Force Model
4.5.1 Bargaining Power of Suppliers
4.5.2 Bargaining Powers of Customers
4.5.3 Threat of New Entrants
4.5.4 Rivalry among Existing Players
4.5.5 Threat of Substitutes
Chapter 5. Point of Care for Sepsis Diagnostics Market – Landscape
5.1 Value Chain Analysis – Key Stakeholders Impact Analysis
5.2 Market Drivers
5.3 Market Restraints/Challenges
5.4 Market Opportunities
Chapter 6. Point of Care for Sepsis Diagnostics Market – By Diagnostic Method
6.1 Introduction/Key Findings
6.2 Biomarker Test
6.3 Molecular Diagnostics
6.4 Immunoassays
6.5 Others
6.6 Y-O-Y Growth trend Analysis By Diagnostic Method
6.7 Absolute $ Opportunity Analysis By Diagnostic Method, 2024-2030
Chapter 7. Point of Care for Sepsis Diagnostics Market – By End-User
7.1 Introduction/Key Findings
7.2 Hospitals & Clinics
7.3 Homecare
7.4 Research Laboratories
7.5 Others
7.6 Y-O-Y Growth trend Analysis By End-User
7.7 Absolute $ Opportunity Analysis By End-User, 2024-2030
Chapter 8. Point of Care for Sepsis Diagnostics Market – By Pathogen
8.1 Introduction/Key Findings
8.2 Bacteria
8.3 Fungal
8.4 Viral
8.5 Y-O-Y Growth trend Analysis By Pathogen
8.6 Absolute $ Opportunity Analysis By Pathogen, 2024-2030
Chapter 9. Point of Care for Sepsis Diagnostics Market – By Age
9.1 Introduction/Key Findings
9.2 Pediatric
9.3 Adult
9.4 Geriatric
9.5 Y-O-Y Growth trend Analysis End-User
9.6 Absolute $ Opportunity Analysis End-User, 2024-2030
Chapter 10. Point of Care for Sepsis Diagnostics Market, By Geography – Market Size, Forecast, Trends & Insights
10.1 North America
10.1.1 By Country
10.1.1.1 U.S.A.
10.1.1.2 Canada
10.1.1.3 Mexico
10.1.2 By Diagnostic Method
10.1.2.1 By Age
10.1.3 By By Pathogen
10.2 By End-User
10.2.1 Countries & Segments - Market Attractiveness Analysis
10.3 Europe
10.3.1 By Country
10.3.1.1 U.K
10.3.1.2 Germany
10.3.1.3 France
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Europe
10.3.2 By Diagnostic Method
10.3.3 By End-User
10.3.4 By By Pathogen
10.3.5 By Age
10.3.6 Countries & Segments - Market Attractiveness Analysis
10.4 Asia Pacific
10.4.1 By Country
10.4.1.1 China
10.4.1.2 Japan
10.4.1.3 South Korea
10.4.1.4 India
10.4.1.5 Australia & New Zealand
10.4.1.6 Rest of Asia-Pacific
10.4.2 By Diagnostic Method
10.4.3 By End-User
10.4.4 By By Pathogen
10.4.5 By Age
10.4.6 Countries & Segments - Market Attractiveness Analysis
10.5 South America
10.5.1 By Country
10.5.1.1 Brazil
10.5.1.2 Argentina
10.5.1.3 Colombia
10.5.1.4 Chile
10.5.1.5 Rest of South America
10.5.2 By Diagnostic Method
10.5.3 By End-User
10.5.4 By By Pathogen
10.5.5 By Age
10.5.6 Countries & Segments - Market Attractiveness Analysis
10.6 Middle East & Africa
10.6.1 By Country
10.6.1.1 United Arab Emirates (UAE)
10.6.1.2 Saudi Arabia
10.6.1.3 Qatar
10.6.1.4 Israel
10.6.1.5 South Africa
10.6.1.6 Nigeria
10.6.1.7 Kenya
10.6.1.8 Egypt
10.6.1.9 Rest of MEA
10.6.2 By Diagnostic Method
10.6.3 By End-User
10.6.4 By By Pathogen
10.6.5 By Age
10.6.6 Countries & Segments - Market Attractiveness Analysis
Chapter 11. Point of Care for Sepsis Diagnostics Market – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
11.1 Siemens
11.2 Abbott
11.3 AdvanDx
11.4 Miacom Diagnostics
11.5 Biofire Diagnostics
11.6 Alteco Medical
11.7 Becton Dickinson
11.8 Wolters Kluwer
11.9 Immunexpress
11.10 Inflammatix
11.11 Mbio
11.12 Abionic
Segmentation
Point of Care For Sepsis Diagnostics Market Segmentation: By Diagnostic Method
- Biomarker Test
- Molecular Diagnostics
- Immunoassays
- Others
In 2022, concerning diagnostic method segmentation, biomarker tests held the predominant market share at approximately 25.5%. These tests involve scrutinizing specific markers in the patient's blood to detect the presence of sepsis. Commonly utilized biomarkers include procalcitonin, C-reactive protein, cytokines, among others. The growth in this category is attributed to enhanced efficiency and the swift delivery of results, aiding in formulating sepsis treatment plans and assessing patient responses.
The fastest-growing segment during the forecast period is molecular diagnostics. This methodology facilitates the detection of sepsis-causing pathogens through genetic analysis, typically involving DNA or RNA sequencing. Molecular diagnostics contribute to rapid result delivery by examining various bodily fluids such as blood, urine, and cerebrospinal fluid. Additionally, portable devices like blood analyzers further support the expeditious diagnostic process.
Point of Care For Sepsis Diagnostics Market Segmentation: By End-User
- Hospitals & Clinics
- Homecare
- Research Laboratories
- Others
In 2022, within the end-user segmentation, hospitals and clinics led with a market share of approximately 32%. These healthcare facilities extensively employ various devices for on-site sepsis diagnosis, allowing immediate testing and subsequent treatment based on the results. Furthermore, Point of Care (POC) monitoring devices are utilized in hospitals to track patient progress and responses to treatments, facilitating prompt interventions in emergency situations.
The homecare segment is the most rapidly expanding category. Post-pandemic, there is a rising trend in homecare testing and monitoring, fueling the demand for POC diagnostic devices for sepsis. These devices enable individuals to conduct tests detecting early signs of infection and offer telemonitoring and teleconsultation services. Integration with mobile apps facilitates remote monitoring, particularly for vulnerable populations like geriatric patients.
Point of Care For Sepsis Diagnostics Market Segmentation: By Pathogen
- Bacteria
- Fungal
- Viral
In 2022, based on pathogen segmentation, bacteria claimed the largest market share at around 30%. Bacterial sepsis diagnostics focus on identifying common bacteria associated with sepsis, including Staphylococcus aureus, E. coli, and Klebsiella pneumoniae. Testing devices include blood culture systems, molecular diagnostic devices, rapid testing tools, and sensitivity testing.
The viral segment exhibits the highest growth during the forecast period. This involves diagnosing virus severity in sepsis, covering viruses directly or indirectly linked to sepsis (adenoviruses, influenza viruses, herpes simplex virus, etc.). Diagnostic techniques include nucleic acid testing, biomarker/diagnostic marker testing, and serological testing.
Point of Care For Sepsis Diagnostics Market Segmentation: By Age
- Pediatric
- Adult
- Geriatric
In 2022, concerning age-based segmentation, the geriatric segment held the majority market share at approximately 36%. Sepsis is often diagnosed in the elderly due to their susceptibility to medical conditions such as respiratory issues, diabetes, and immunodeficiency viruses. POC diagnostics meet the demand for at-home testing, enabling family members to monitor the health of the elderly remotely.
The pediatric segment is the most rapidly growing during the forecast period. Children, especially those under 14 and infants, may develop sepsis due to injuries, inflammation, infections, or untreated existing diseases. POC diagnostics aid in early sepsis detection in children, reducing the risk of future complications and assisting healthcare professionals in devising preventive treatments.
Point of Care For Sepsis Diagnostics Market Segmentation: Regional Analysis
- North America
- Europe
- Asia-Pacific
- South America
- Middle-East & Africa
In 2022, regional segmentation indicated that North America dominated the market with a share of about 38%. The region's advanced diagnostic devices and robust healthcare infrastructure contribute to the high demand for point-of-care sepsis diagnostics.
Asia-Pacific emerges as the fastest-growing region during the forecast period. Increasing demand for on-site diagnosis, growing trends in telehealth and telemedicine, and government support for the healthcare sector drive the demand for point-of-care sepsis diagnostics in the region.
COVID-19 Impact Analysis on the Point of Care For Sepsis Diagnostics Market:
The pandemic significantly influenced the point-of-care sepsis diagnostics market, witnessing increased demand for detecting diseases due to the virus outbreak. Sepsis, being an infectious disease, experienced heightened testing requirements. However, the shift in focus towards treating virus-infected patients resulted in a decline in demand for POCT for sepsis diagnostics. Despite this, increased digitization during the pandemic facilitated the adoption of telehealth and telemedicine services, mitigating delays in patient treatment.
Latest Developments:
Constant product innovations, rising consumer demand for early detection and rapid delivery testing devices, and increasing trends in telehealth contribute to the growing demand for point-of-care sepsis diagnostics.
In November 2022, Immunexpress introduced SepiCyte Rapid, a rapid testing device for sepsis. This product enables fast sepsis diagnosis directly from a blood draw, utilizing PCR technology to detect mRNA signatures, evaluating the severity of bacterial or pathogenic infections.
Key Players:
- Siemens
- Abbott
- AdvanDx
- Miacom Diagnostics
- Biofire Diagnostics
- Alteco Medical
- Becton Dickinson
- Wolters Kluwer
- Immunexpress
- Inflammatix
- Mbio
- Abionic
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.